Targeted Therapies for Neuroendocrine Neoplasms
Authors: MD, PhD Heloisa Prado Soares, MD Jonathan Strosberg
Publisher: Springer New York
Neuroendocrine tumors are rare but have increased in incidence over the last several decades. Significant advances in the understanding of the molecular biology of these tumors have led to new treatment options. Somatostatin analogs were the first targeted therapy for neuroendocrine tumors. Several other targeted therapies have subsequently established a role in the management of these diseases. In this chapter, we will describe currently available targeted therapies for neuroendocrine tumors and review the clinical status of promising investigational therapies.